Literature DB >> 2619783

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial.

H Iso1, D R Jacobs, D Wentworth, J D Neaton, J D Cohen.   

Abstract

We examined the relation between the serum total cholesterol level and the risk of death from stroke during six years of follow-up in 350,977 men, 35 to 57 years of age, who had no history of heart attack and were not currently being treated for diabetes mellitus. The diagnosis of stroke and the type of stroke were obtained from death certificates. Using proportional-hazards regression to control for age, cigarette smoking, diastolic blood pressure, and race or ethnic group, we found that the six-year risk of death from intracranial hemorrhage (International Classification of Diseases, ninth edition [ICD-9], categories 431 and 432) was three times higher in men with serum cholesterol levels under 4.14 mmol per liter (160 mg per deciliter) than in those with higher cholesterol levels (P = 0.05 by omnibus test across five cholesterol levels). On the other hand, a positive association was observed between the serum cholesterol level and death from nonhemorrhagic stroke (P = 0.007). The inverse association of the serum cholesterol level with the risk of death from intracranial hemorrhage was confined to men with diastolic blood pressure greater than or equal to 90 mm Hg, in whom death from intracranial hemorrhage is relatively common. We conclude that there is an inverse relation between the serum cholesterol level and the risk of death from hemorrhagic stroke in middle-aged American men, but that its public health impact is overwhelmed by the positive association of higher serum cholesterol levels with death from nonhemorrhagic stroke and total cardiovascular disease (ICD-9 categories 390 through 459).

Entities:  

Keywords:  Americas; Biology; Cerebrovascular Effects--men; Cholesterol; Demographic Factors; Developed Countries; Developing Countries; Follow-up Studies; Lipids; Mortality; North America; Northern America; Physiology; Population; Population Dynamics; Research Methodology; Risk Factors; Studies; United States

Mesh:

Substances:

Year:  1989        PMID: 2619783     DOI: 10.1056/NEJM198904063201405

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  177 in total

1.  HMG coenzyme A reductase inhibitors: good news and bad news.

Authors:  M J Klag
Journal:  J Gen Intern Med       Date:  1999-12       Impact factor: 5.128

2.  Do statins afford neuroprotection in patients with cerebral ischaemia and stroke?

Authors:  C J Vaughan; N Delanty; C T Basson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.

Authors:  M H Davidson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Transient Ischemic Attack and Secondary Stroke.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.598

5.  Reflections on the U.S. Preventive Services Task Force recommendations for screening for hypertension and hypercholesterolemia.

Authors:  P K Whelton
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

Review 6.  [End-organ damage in hyperlipidemias].

Authors:  M Faust; W Krone
Journal:  Internist (Berl)       Date:  2003-07       Impact factor: 0.743

7.  The US decline in stroke mortality: what does ecological analysis tell us?

Authors:  D R Jacobs; P G McGovern; H Blackburn
Journal:  Am J Public Health       Date:  1992-12       Impact factor: 9.308

Review 8.  [Risk factors in ischemic stroke. Review of evidence in primary prevention].

Authors:  M Weih; J Müller-Nordhorn; N Amberger; F Masuhr; F Lürtzing; J P Dreier; A Hetzel
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

9.  Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women.

Authors:  Jeffrey S Berger; Aileen P McGinn; Barbara V Howard; Lewis Kuller; Joann E Manson; Jim Otvos; J David Curb; Charles B Eaton; Robert C Kaplan; John K Lynch; Daniel M Rosenbaum; Sylvia Wassertheil-Smoller
Journal:  Stroke       Date:  2012-02-02       Impact factor: 7.914

10.  Trans-sodium crocetinate provides neuroprotection against cerebral ischemia and reperfusion in obese mice.

Authors:  Jiao Deng; Lize Xiong; Zhiyi Zuo
Journal:  J Neurosci Res       Date:  2014-12-09       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.